Test drug choice after breast surgery for hormone-negative breast cancer
Part of Cancer, Skin clinical trials.
This study compares an “albumin-bound” form of paclitaxel versus other taxane chemotherapy options after breast surgery. It’s for people with HER2-negative, higher-risk breast cancer to see which approach works better in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were assigned female at birth and are between 18 and 70 years old
- Your breast cancer is confirmed as invasive breast cancer (not just abnormal cells)
- You finished surgery with the whole tumor removed, and the edges (“margins”) are clear
- Your plan is to take AC-T chemotherapy after surgery (a common chemo sequence used in early breast cancer)
- Your heart function is strong enough (left heart pumping ability, LVEF, is at least 50%)
- Your cancer is HER2-negative and “high risk,” such as many affected lymph nodes, a large tumor, or specific tumor features (like grade 3 or high Ki-67)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This trial tests which chemotherapy drug works better before surgery (neoadjuvant therapy) for triple-negative breast cancer that has spread to underarm lymph nodes. It compares two forms of paclitaxel given by random assignment to see which option may shrink the tumor more effectively and improve outcomes.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This Phase 4 study tests an additional (adjuvant) treatment for breast cancer after surgery and standard follow-up care. It may help lower the chance the cancer comes back, but you must match specific tumor and body-chemistry requirements to join.
This Phase 1 study tests different chemotherapy approaches in people with breast cancer that has been surgically removed but is early stage. It aims to find a chemotherapy plan that’s safe and works well right after surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.